Novo Nordisk Earnings Reports

Novo Nordisk delivered solid sales growth in Q3 2025, especially in obesity care, but saw a 27% drop in net income primarily due to DKK 9 billion in restructuring charges tied to a company-wide transformation.

Novo Nordisk delivered solid financial performance in Q2 2025, with double-digit growth in revenue, operating profit, and net income. Obesity care was the main growth engine, offsetting challenges related to compounded GLP-1 competition in the U.S.

Novo Nordisk delivered a robust Q1 2025, with sales growing 19% and net profit rising 28%, fueled by continued demand for GLP-1 therapies and expanding market presence in obesity care.